Literature DB >> 19205968

Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.

Nicola Conran1, Carla F Franco-Penteado, Fernando F Costa.   

Abstract

Sickle cell disease is an inherited disorder of hemoglobin (Hb) synthesis, caused by a single nucleotide substitution (GTG>GAG) at the sixth codon of the beta-globin gene, leading to the production of a defective form of Hb, Hb S. When deoxygenated, Hb S polymerizes, damaging the sickle erythrocyte and it is this polymerization that is the primary indispensable event in the molecular pathogenesis of sickle cell disease. Hb S polymerization results in a series of cellular alterations in red cell morphology and function that shorten the red cell life span and leads to vascular occlusion. Sickle cell disease vaso-occlusion is now known to constitute a complex multifactorial process characterized by recurrent vaso-occlusion, ischemia-reperfusion injury, and oxidative stress with consequent vascular endothelial cell activation that induces a chronic inflammatory state in sickle cell disease individual and is propagated by elevated levels of circulating inflammatory cytokines. Activation of the endothelium results in the induction of endothelial adhesion molecule expression that mediates red and white cell adhesion to the vessel wall and the formation of heterocellular aggregates, followed by secondary red cell trapping, all of which contribute to reduced blood flow and eventually obstruction of the micro-circulation. Reduced nitric oxide bioavailability, caused principally by its consumption by cell-free Hb, liberated during intravascular hemolysis, contributes to this process by facilitating vasoconstriction and adhesion molecule activity.

Entities:  

Mesh:

Year:  2009        PMID: 19205968     DOI: 10.1080/03630260802625709

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  41 in total

1.  Epinephrine modulates BCAM/Lu and ICAM-4 expression on the sickle cell trait red blood cell membrane.

Authors:  Jamie L Maciaszek; Biree Andemariam; Greg Huber; George Lykotrafitis
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

2.  Carbon-fiber microelectrode amperometry reveals sickle-cell-induced inflammation and chronic morphine effects on single mast cells.

Authors:  Benjamin M Manning; Robert P Hebbel; Kalpna Gupta; Christy L Haynes
Journal:  ACS Chem Biol       Date:  2012-01-23       Impact factor: 5.100

3.  Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes.

Authors:  Carlton D Dampier; Wally R Smith; Hae-Young Kim; Carrie Greene Wager; Margaret C Bell; Caterina P Minniti; Jeffrey Keefer; Lewis Hsu; Lakshmanan Krishnamurti; A Kyle Mack; Donna McClish; Sonja M McKinlay; Scott T Miller; Ifeyinwa Osunkwo; Phillip Seaman; Marilyn J Telen; Debra L Weiner
Journal:  Am J Hematol       Date:  2011-09-22       Impact factor: 10.047

4.  Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease.

Authors:  Emmanuil S Hatzipantelis; Zoe Dorothea Pana; N Gombakis; A Taparkou; V Tzimouli; D Kleta; D J Zafeiriou; V Garipidou; F Kanakoudi; M Athanassiou
Journal:  Int J Hematol       Date:  2013-06-27       Impact factor: 2.490

5.  Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease.

Authors:  Ashaunta Tumblin; Anitaben Tailor; Gerard T Hoehn; A Kyle Mack; Laurel Mendelsohn; Lita Freeman; Xiuli Xu; Alan T Remaley; Peter J Munson; Anthony F Suffredini; Gregory J Kato
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

6.  Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology.

Authors:  Pedro Cabrales; Graziela M Zanini; Diana Meays; John A Frangos; Leonardo J M Carvalho
Journal:  J Infect Dis       Date:  2011-03-16       Impact factor: 5.226

7.  Simvastatin abrogates inflamed neutrophil adhesive properties, in association with the inhibition of Mac-1 integrin expression and modulation of Rho kinase activity.

Authors:  Angélica Aparecida Antoniellis Silveira; Venina Marcela Dominical; Mariana Lazarini; Fernando Ferreira Costa; Nicola Conran
Journal:  Inflamm Res       Date:  2012-12-19       Impact factor: 4.575

Review 8.  Hypoxia and inflammation in children with sickle cell disease: implications for hippocampal functioning and episodic memory.

Authors:  Mary Iampietro; Tania Giovannetti; Reem Tarazi
Journal:  Neuropsychol Rev       Date:  2014-04-18       Impact factor: 7.444

9.  Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.

Authors:  Danilo Grunig Humberto Silva; Edis Belini Junior; Gisele Cristine de Souza Carrocini; Lidiane de Souza Torres; Octávio Ricci Júnior; Clarisse Lopes de Castro Lobo; Claudia Regina Bonini-Domingos; Eduardo Alves de Almeida
Journal:  BMC Med Genet       Date:  2013-10-09       Impact factor: 2.103

10.  Acute silent cerebral ischemic events in children with sickle cell anemia.

Authors:  Charles T Quinn; Robert C McKinstry; Michael M Dowling; William S Ball; Michael A Kraut; James F Casella; Nomazulu Dlamini; Rebecca N Ichord; Lori C Jordan; Fenella J Kirkham; Michael J Noetzel; E Steve Roach; John J Strouse; Janet L Kwiatkowski; Deborah Hirtz; Michael R DeBaun
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.